ReviewDermatology practical & conceptual2020
Melanoma Epidemiology and Early Detection in Europe: Diversity and Disparities.
Review in Dermatology practical & conceptual, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review of microsimulation models for skin cancer.BMC medical informatics and decision making · 2025Pooled it
- Retention and Evaluation of Precision and Generic Prevention Materials for Melanoma: A Qualitative Study Comparing Young Adults and Adults.Cancer prevention research (Philadelphia, Pa.) · 2022Trial
- Real-World Use of Adjuvant Nivolumab for Resected Stage III-IV Melanoma: 2-Year Analysis of AdjuMel.Dermatology and therapy · 2026Article
- Risk of subsequent primary melanoma in 68 002 five-year survivors of childhood and adolescent cancer in Europe: the PanCareSurFup cohort study.Journal of the National Cancer Institute · 2026Article
- Article
- Targeting sFRP1 with WAY-316606 Suppresses Proliferation, Migration, and Invasion in Metastatic Melanoma.Cancers · 2026Article
- Trends in Incidence and Mortality of Primary Cutaneous Melanoma in Serbia Between 2008 and 2022.Medicina (Kaunas, Lithuania) · 2026Article
- Article
- European Code Against Cancer, 5th edition - ultraviolet radiation, radon and cancer.Molecular oncology · 2026Review
- Exploring the Link Between PACAP Signalling and Hyaluronic Acid Production in Melanoma Progression.International journal of molecular sciences · 2025Article
- Personalized therapies in advanced BRAFV600-mutated melanoma: review based on 3 case reports of the REMINISCENCE project.Melanoma management · 2025Review
- Ten Years of Euromelanoma in Hungary: Nationwide Trends and Risk Factors for Skin Cancer in Central-Eastern Europe.Cancers · 2025Article
- Research Progress of Natural Compounds from Chinese Herbal Medicine in the Treatment of Melanoma.Current treatment options in oncology · 2025Review
- Malignant melanoma in Portuguese adult population: a scoping review of the real-world evidence.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- Advances in computer vision and deep learning-facilitated early detection of melanoma.Briefings in functional genomics · 2025Review
- Melanoma in Peru: 1000 patients and 10 years of experience.PloS one · 2025Article
- Isolation of the Surfaceome from Primary Human Epidermal Melanocytes Using Glycocapture and Shotgun Proteomics.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Preliminary analysis of the melanoma multimedia educational program for general practitioners on behalf of the Italian Melanoma Intergroup.Dermatology reports · 2024Article
- Evaluation of a training course for general practitioners within the melanoma multimedia education programme of the Italian Melanoma Intergroup: a study protocol.Dermatology reports · 2024Article
- Evaluation of Demographic and Clinical Characteristics of Turkish Patients With Primary Cutaneous Melanoma: A 5-Year Experience of a Tertiary Referral Center.Dermatology practical & conceptual · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melanoma claims annually more than 20,000 lives in Europe and is an important public health burden through its continuously increasing incidence and with its high mortality, costs, and complexity of care in advanced stages. Epidemiological surveillance is indispensable for the research into its causes, new prognostic markers, and innovative therapies, as well as for the building of efficient cancer control plans. However, important differences in the sources and availability of accurate epidemiological data exist among European countries and regions, contributing to a heterogeneous picture with 20-fold differences in the reported national melanoma incidence rates, divergent mortality trends, and solid disparities in survival across the Continent. Countries in the eastern half of Europe report the lowest incidence rates, but high case fatality, persisting and increasing mortality, a higher proportion of thicker tumors and late diagnosis, and lower survival rates. They are the least well equipped with quality cancer registration and reporting, and they lag behind in efficient cancer control plans implementation. This review highlights the main differences in melanoma epidemiology across Europe, together with an insight into their underlying causes in the areas of melanoma registration, early diagnosis, and prevention. These differences should be acknowledged and understood by physicians, researchers, and all stakeholders involved in improving melanoma care and outcomes, as no one-size-fits-all solution can tackle the melanoma problem in Europe. Instead, there is a need for nuanced strategies, adapted to the heterogeneous national and regional contexts, that would build on European diversity to eliminate the outcome disparities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.